The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m2 intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myelodysplastic syndrome or acute leukemia

Anne Wanquet, Roberto Crocchiolo, Sabine Furst, Angela Granata, Catherine Faucher, Raynier Devillier, Samia Harbi, Claude Lemarie, Boris Calmels, Norbert Vey, Pierre Jean Weiller, Christian Chabannon, Luca Castagna, Didier Blaise, Jean El-Cheikh

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The optimal intensity of myeloablation associated with a reduced-toxicity conditioning (RTC) regimen in order to decrease the relapse rate without increasing non-relapse mortality (NRM), is not well established yet. This retrospective analysis was done on 30 patients with hematological malignancies. The aim was to assess the safety of a RTC regimen based on the busulfan at a dose of 100 mg/m2/d intravenously for 4 d, fludarabine at a dose of 30 mg/m2/d for 5 d, and anti-thymoglobulins at a dose of 2.5 mg/kg/d for 2 d. The cumulative incidences of grade 2–4 acute graft-versus-host disease (GVHD) and all grades chronic GVHD were 37% and 42%, respectively. Median 1-year overall survival and disease-free survival were 66% and 50%, respectively. At 1 year, the cumulative incidence of relapse/disease progression was 33%. NRM was 3% and 17% at day 100 and 1 year, respectively. This RTC conditioning regimen can lead to a long-term disease control. Moreover, it appears to be safe with a low NRM rate among high-risk patients.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalLeukemia and Lymphoma
DOIs
Publication statusAccepted/In press - Feb 12 2016

Fingerprint

Busulfan
Antilymphocyte Serum
Myelodysplastic Syndromes
Stem Cell Transplantation
Leukemia
Graft vs Host Disease
Safety
Mortality
Recurrence
Incidence
Hematologic Neoplasms
Disease-Free Survival
Disease Progression
Survival
fludarabine

Keywords

  • Allogeneic stem cell transplantation
  • intravenous busulfan
  • reduced toxicity conditioning

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m2 intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myelodysplastic syndrome or acute leukemia. / Wanquet, Anne; Crocchiolo, Roberto; Furst, Sabine; Granata, Angela; Faucher, Catherine; Devillier, Raynier; Harbi, Samia; Lemarie, Claude; Calmels, Boris; Vey, Norbert; Weiller, Pierre Jean; Chabannon, Christian; Castagna, Luca; Blaise, Didier; El-Cheikh, Jean.

In: Leukemia and Lymphoma, 12.02.2016, p. 1-6.

Research output: Contribution to journalArticle

Wanquet, Anne ; Crocchiolo, Roberto ; Furst, Sabine ; Granata, Angela ; Faucher, Catherine ; Devillier, Raynier ; Harbi, Samia ; Lemarie, Claude ; Calmels, Boris ; Vey, Norbert ; Weiller, Pierre Jean ; Chabannon, Christian ; Castagna, Luca ; Blaise, Didier ; El-Cheikh, Jean. / The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m2 intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myelodysplastic syndrome or acute leukemia. In: Leukemia and Lymphoma. 2016 ; pp. 1-6.
@article{c88845d1f9eb4b4cabcee5537c0f04c4,
title = "The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m2 intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myelodysplastic syndrome or acute leukemia",
abstract = "The optimal intensity of myeloablation associated with a reduced-toxicity conditioning (RTC) regimen in order to decrease the relapse rate without increasing non-relapse mortality (NRM), is not well established yet. This retrospective analysis was done on 30 patients with hematological malignancies. The aim was to assess the safety of a RTC regimen based on the busulfan at a dose of 100 mg/m2/d intravenously for 4 d, fludarabine at a dose of 30 mg/m2/d for 5 d, and anti-thymoglobulins at a dose of 2.5 mg/kg/d for 2 d. The cumulative incidences of grade 2–4 acute graft-versus-host disease (GVHD) and all grades chronic GVHD were 37{\%} and 42{\%}, respectively. Median 1-year overall survival and disease-free survival were 66{\%} and 50{\%}, respectively. At 1 year, the cumulative incidence of relapse/disease progression was 33{\%}. NRM was 3{\%} and 17{\%} at day 100 and 1 year, respectively. This RTC conditioning regimen can lead to a long-term disease control. Moreover, it appears to be safe with a low NRM rate among high-risk patients.",
keywords = "Allogeneic stem cell transplantation, intravenous busulfan, reduced toxicity conditioning",
author = "Anne Wanquet and Roberto Crocchiolo and Sabine Furst and Angela Granata and Catherine Faucher and Raynier Devillier and Samia Harbi and Claude Lemarie and Boris Calmels and Norbert Vey and Weiller, {Pierre Jean} and Christian Chabannon and Luca Castagna and Didier Blaise and Jean El-Cheikh",
year = "2016",
month = "2",
day = "12",
doi = "10.3109/10428194.2016.1146948",
language = "English",
pages = "1--6",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",

}

TY - JOUR

T1 - The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m2 intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myelodysplastic syndrome or acute leukemia

AU - Wanquet, Anne

AU - Crocchiolo, Roberto

AU - Furst, Sabine

AU - Granata, Angela

AU - Faucher, Catherine

AU - Devillier, Raynier

AU - Harbi, Samia

AU - Lemarie, Claude

AU - Calmels, Boris

AU - Vey, Norbert

AU - Weiller, Pierre Jean

AU - Chabannon, Christian

AU - Castagna, Luca

AU - Blaise, Didier

AU - El-Cheikh, Jean

PY - 2016/2/12

Y1 - 2016/2/12

N2 - The optimal intensity of myeloablation associated with a reduced-toxicity conditioning (RTC) regimen in order to decrease the relapse rate without increasing non-relapse mortality (NRM), is not well established yet. This retrospective analysis was done on 30 patients with hematological malignancies. The aim was to assess the safety of a RTC regimen based on the busulfan at a dose of 100 mg/m2/d intravenously for 4 d, fludarabine at a dose of 30 mg/m2/d for 5 d, and anti-thymoglobulins at a dose of 2.5 mg/kg/d for 2 d. The cumulative incidences of grade 2–4 acute graft-versus-host disease (GVHD) and all grades chronic GVHD were 37% and 42%, respectively. Median 1-year overall survival and disease-free survival were 66% and 50%, respectively. At 1 year, the cumulative incidence of relapse/disease progression was 33%. NRM was 3% and 17% at day 100 and 1 year, respectively. This RTC conditioning regimen can lead to a long-term disease control. Moreover, it appears to be safe with a low NRM rate among high-risk patients.

AB - The optimal intensity of myeloablation associated with a reduced-toxicity conditioning (RTC) regimen in order to decrease the relapse rate without increasing non-relapse mortality (NRM), is not well established yet. This retrospective analysis was done on 30 patients with hematological malignancies. The aim was to assess the safety of a RTC regimen based on the busulfan at a dose of 100 mg/m2/d intravenously for 4 d, fludarabine at a dose of 30 mg/m2/d for 5 d, and anti-thymoglobulins at a dose of 2.5 mg/kg/d for 2 d. The cumulative incidences of grade 2–4 acute graft-versus-host disease (GVHD) and all grades chronic GVHD were 37% and 42%, respectively. Median 1-year overall survival and disease-free survival were 66% and 50%, respectively. At 1 year, the cumulative incidence of relapse/disease progression was 33%. NRM was 3% and 17% at day 100 and 1 year, respectively. This RTC conditioning regimen can lead to a long-term disease control. Moreover, it appears to be safe with a low NRM rate among high-risk patients.

KW - Allogeneic stem cell transplantation

KW - intravenous busulfan

KW - reduced toxicity conditioning

UR - http://www.scopus.com/inward/record.url?scp=84958550624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958550624&partnerID=8YFLogxK

U2 - 10.3109/10428194.2016.1146948

DO - 10.3109/10428194.2016.1146948

M3 - Article

AN - SCOPUS:84958550624

SP - 1

EP - 6

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

ER -